Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Ramucirumab> ?p ?o }
Showing triples 1 to 88 of
88
with 100 triples per page.
- Ramucirumab abstract "Ramucirumab (IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.".
- Ramucirumab atcPrefix "none".
- Ramucirumab casNumber "947687-13-0".
- Ramucirumab fdaUniiCode "D99YVK4L0X".
- Ramucirumab wikiPageID "19841090".
- Ramucirumab wikiPageLength "4768".
- Ramucirumab wikiPageOutDegree "25".
- Ramucirumab wikiPageRevisionID "665028952".
- Ramucirumab wikiPageWikiLink Adenocarcinoma.
- Ramucirumab wikiPageWikiLink Anaplastic_lymphoma_kinase.
- Ramucirumab wikiPageWikiLink Angiogenesis.
- Ramucirumab wikiPageWikiLink Atomic_mass_unit.
- Ramucirumab wikiPageWikiLink Breast_cancer.
- Ramucirumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Ramucirumab wikiPageWikiLink Docetaxel.
- Ramucirumab wikiPageWikiLink Dyax.
- Ramucirumab wikiPageWikiLink Eli_Lilly.
- Ramucirumab wikiPageWikiLink Epidermal_growth_factor_receptor.
- Ramucirumab wikiPageWikiLink Food_and_Drug_Administration.
- Ramucirumab wikiPageWikiLink ImClone_Systems.
- Ramucirumab wikiPageWikiLink KDa.
- Ramucirumab wikiPageWikiLink Kinase_insert_domain_receptor.
- Ramucirumab wikiPageWikiLink Monoclonal_antibody.
- Ramucirumab wikiPageWikiLink Non-small-cell_lung_carcinoma.
- Ramucirumab wikiPageWikiLink Paclitaxel.
- Ramucirumab wikiPageWikiLink Phage_display.
- Ramucirumab wikiPageWikiLink Phage_display_library.
- Ramucirumab wikiPageWikiLink Platinum-based_antineoplastic.
- Ramucirumab wikiPageWikiLink Platinum-containing_anti-cancer_drug.
- Ramucirumab wikiPageWikiLink Pyrimidine_analog.
- Ramucirumab wikiPageWikiLink Pyrimidine_analogue.
- Ramucirumab wikiPageWikiLink Receptor_antagonist.
- Ramucirumab wikiPageWikiLink Stomach_cancer.
- Ramucirumab wikiPageWikiLink Targeted_therapy.
- Ramucirumab wikiPageWikiLink VEGFR2.
- Ramucirumab wikiPageWikiLink Vascular_endothelial_growth_factor.
- Ramucirumab wikiPageWikiLink Vascular_endothelial_growth_factor_receptor_2.
- Ramucirumab wikiPageWikiLinkText "Cyramza".
- Ramucirumab wikiPageWikiLinkText "Ramucirumab".
- Ramucirumab wikiPageWikiLinkText "ramucirumab".
- Ramucirumab atcPrefix "none".
- Ramucirumab c "6374".
- Ramucirumab casNumber "947687".
- Ramucirumab chemspiderid "NA".
- Ramucirumab h "9864".
- Ramucirumab hasPhotoCollection Ramucirumab.
- Ramucirumab legalStatus "Approved".
- Ramucirumab mabType "mab".
- Ramucirumab molecularWeight "143.6".
- Ramucirumab n "1692".
- Ramucirumab o "1996".
- Ramucirumab s "46".
- Ramucirumab source "u".
- Ramucirumab target Kinase_insert_domain_receptor.
- Ramucirumab target VEGFR2.
- Ramucirumab tradename "Cyramza".
- Ramucirumab type "mab".
- Ramucirumab unii "D99YVK4L0X".
- Ramucirumab verifiedfields "changed".
- Ramucirumab verifiedrevid "464380023".
- Ramucirumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Ramucirumab wikiPageUsesTemplate Template:Drugbox.
- Ramucirumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Ramucirumab wikiPageUsesTemplate Template:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems.
- Ramucirumab subject Category:Monoclonal_antibodies.
- Ramucirumab type Article.
- Ramucirumab type ChemicalSubstance.
- Ramucirumab type Drug.
- Ramucirumab type Antibody.
- Ramucirumab type Article.
- Ramucirumab type Chemical.
- Ramucirumab type Drug.
- Ramucirumab type ChemicalObject.
- Ramucirumab type Thing.
- Ramucirumab type Q8386.
- Ramucirumab comment "Ramucirumab (IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis. This drug was developed by ImClone Systems Inc.".
- Ramucirumab label "Ramucirumab".
- Ramucirumab sameAs Ramucirumab.
- Ramucirumab sameAs Ramucirumab.
- Ramucirumab sameAs Ramucirumab.
- Ramucirumab sameAs ラムシルマブ.
- Ramucirumab sameAs Ramucirumabas.
- Ramucirumab sameAs m.04q28k_.
- Ramucirumab sameAs Рамуцирумаб.
- Ramucirumab sameAs Q7290345.
- Ramucirumab sameAs Q7290345.
- Ramucirumab wasDerivedFrom Ramucirumab?oldid=665028952.
- Ramucirumab isPrimaryTopicOf Ramucirumab.